<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Transplant_Drugs" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Transplant_Drugs</book-part-id>
      <title-group>
        <title>Transplant Agents</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>2</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Trandolapril" document-type="chapter">Trandolapril</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Tranylcypromine" document-type="chapter">Tranylcypromine</related-object>
    </book-part-meta>
    <body>
      <sec id="Transplant_Drugs.OVERVIEW">
        <title>OVERVIEW</title>
        <p content-type="pubmed-excerpt">Solid organ transplantation has been made possible by the development of potent immunosuppressive agents which block cellular rejection adequately for survival of the transplanted organ and induction of at least partial tolerance. The first regimens that were found to successfully prevent cellular rejection consisted of high doses of corticosteroids and an immunosuppressive antimetabolite such as azathioprine, 6-mercaptopurine or cyclophosphamide. These combinations allowed for the initial successes in renal, liver, lung and heart transplantation in the 1950s and 1960s. However, acute and chronic rejection as well as complications of high dose corticosteroid therapy remained major problems. The subsequent introduction of the calcineurin inhibitors, cyclosporine and tacrolimus in the 1980s placed organ transplantation on a solid basis, leading to its acceptance as the standard of care for end-stage kidney, liver, heart and lung disease. The further addition of the newer, more specific antiproliferative and immunosuppressive agents&#x02013;mycophenolate mofetil (1995) and sirolimus (1999)&#x02013;have further improved the management of patients after solid organ transplantation. All of these agents are associated with mild liver test abnormalities that occur early during therapy or shortly after transplantation and that resolve rapidly with dose modification. While these potent immunosuppressive agents all have some degree of liver toxicity, clinically significant injury is rare and has invariably been mild and rapidly reversible with dose modification or switching to another agent. These agents are often used in patients with underlying liver disease or who are receiving multiple potentially hepatotoxic drugs, so that their role in causing hepatic injury is not always clear.</p>
        <p content-type="pubmed-excerpt">The following drugs used to prevent transplant rejection are discussed separately. The references regarding the hepatotoxicity and safety of these agents are given together below.</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="livertox" document-id="AntithymocyteGlobuli" document-type="chapter">Antithymocyte Globulin</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="livertox" document-id="Cyclosporine" document-type="chapter">Cyclosporine</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="livertox" document-id="Mycophenolate" document-type="chapter">Mycophenolate</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="livertox" document-id="Sirolimus" document-type="chapter">Sirolimus</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="livertox" document-id="Tacrolimus" document-type="chapter">Tacrolimus</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="livertox" document-id="MonoclonalAntibodies" document-type="chapter">Monoclonal Antibodies</related-object>
            </p>
          </list-item>
        </list>
        <p>&#x003bf; <related-object link-type="booklink" source-id="livertox" document-id="Alemtuzumab" document-type="chapter">Alemtuzumab</related-object></p>
        <p>&#x003bf; <related-object link-type="booklink" source-id="livertox" document-id="Basiliximab" document-type="chapter">Basiliximab</related-object></p>
        <p>&#x003bf; <related-object link-type="booklink" source-id="livertox" document-id="Daclizumab" document-type="chapter">Daclizumab</related-object></p>
        <p>&#x003bf; <related-object link-type="booklink" source-id="livertox" document-id="Muromonab-CD3" document-type="chapter">Muromonab</related-object></p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="livertox" document-id="Plerixafor" document-type="chapter">Plerixafor</related-object>
            </p>
          </list-item>
        </list>
      </sec>
      <sec id="Transplant_Drugs.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p content-type="pubmed-excerpt">References updated: 17 February 2020</p>
        <ref-list id="Transplant_Drugs.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Transplant_Drugs.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Cyclosporine. Oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 697-8.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; cyclosporine therapy was associated with a high rate of cholestatic liver enzyme elevations ranging from 4-86% and occasional instances of cholestatic hepatitis, some features of which were reproducible in animal models; tacrolimus, sirolimus, and mycophenolate are not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.reuben.2013">
            <mixed-citation publication-type="book">Reuben A. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 569-92.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of immunosuppressive agents mentions that reports of hepatotoxicity of cyclosporine have decreased since the 1980s, perhaps because of monitoring of serum levels and lower doses used; liver injury from tacrolimus, sirolimus and mycophenolate is rare and usually rapidly reversible).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.krensky.2018">
            <mixed-citation publication-type="book">Krensky AM, Azzi JR, Hafler DA. Immnosuppressants and tolerogens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-54.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.klintmalm.1981">
            <mixed-citation publication-type="other">Klintmalm GB, Iwatsuki S, Starzl TE. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 1981; 32:4 88-9.<annotation><p><italic toggle="yes">(Among 66 renal transplant recipients on cyclosporine, 13 [17%] had rise of bilirubin above 2.0 [range 2.1-4.5] mg/dL, with minimal or no change in ALT or Alk P, and all episodes were mild and easily managed by dose reduction).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.kowdley.1995.991">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kowdley</surname>
                  <given-names>KV</given-names>
                </name>
                <name name-style="western">
                  <surname>Keeffe</surname>
                  <given-names>EB</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity of transplant immunosuppressive agents.</article-title>
              <source>Gastroenterol Clin North Am</source>
              <year>1995</year>
              <volume>24</volume>
              <fpage>991</fpage>
              <lpage>1001</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of reports of hepatotoxicity from cyclosporine in form of mild hyperbilirubinemia, mild-to-moderate serum enzyme elevations and biliary sludge and stones).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8749908</pub-id>
            </element-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.russo.2004.1018">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Russo</surname>
                  <given-names>MW</given-names>
                </name>
                <name name-style="western">
                  <surname>Galanko</surname>
                  <given-names>JA</given-names>
                </name>
                <name name-style="western">
                  <surname>Shrestha</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Fried</surname>
                  <given-names>MW</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <article-title>Liver transplantation for acute liver failure from drug-induced liver injury in the United States.</article-title>
              <source>Liver Transpl</source>
              <year>2004</year>
              <volume>10</volume>
              <fpage>1018</fpage>
              <lpage>23</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among ~50,000 liver transplants reported to UNOS between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, 124 for acetaminophen and 137 for other drugs or toxins, but none for agents used to prevent transplant rejection).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15390328</pub-id>
            </element-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were attributed to cyclosporine, tacrolimus, sirolimus or mycophenolate).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reuben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>DG</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WM</given-names>
                </name>
                <collab>Acute Liver Failure Study Group</collab>
              </person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none to an agent used to prevent transplant rejection).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, one was attributed to mycophenolate but none to cyclosporine, sirolimus or tacrolimus).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Transplant_Drugs.REF.chalasani.2015">
            <mixed-citation publication-type="other">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. e7.<annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, one case was attributed to cyclosporine, but none to tacrolimus, sirolimus, or mycophenolate mofetil).</italic></p></annotation></mixed-citation>
          </ref>
        </ref-list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
